Kurs & Likviditet
|Lista||First North Denmark|
|2021-04-28||Ordinarie utdelning VIRO 0.00 DKK|
|2020-06-19||Ordinarie utdelning VIRO 0.00 DKK|
|2019-04-26||Ordinarie utdelning VIRO 0.00 DKK|
2.2.2021 14:07:05 CET | ViroGates | Company Announcement
Company Announcement - No. 3 - 2021
BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, announces the first order from a new clinical routine customer in Spain. The customer, Policlínica Nuestra Señora del Rosario, is a private hospital located in Ibiza. The hospital has around 70 beds offering both acute care treatment and out-patient treatments for locals and tourists. The uptake population of the hospital is approximately 50,000 people. The hospital also has three smaller associated clinics.
The hospital will immediately implement suPARnostic® TurbiLatex on its Roche cobas 501 system. The hospital has decided to start using suPARnostic® based on references from other hospital users in Spain. The hospital wants to use suPARnostic® to improve triaging of COVID-19 patients and also generally of patients in its acute care function.
Jakob Knudsen, Chief Executive Officer of ViroGates, said: ”We are happy to add another clinical customer to our list of already established customers in Spain. We are particularly encouraged to see that this customer has decided to implement suPARnostic® based on data from peers in Spain and abroad without previous on-site experience. This shows that clinical evidence, local reference hospitals and our targeted marketing work in combination to convince customers who have not been acquainted with our products previously.”
The announcement can be found at https://www.virogates.com/investor/announcements
For further information, please contact:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: firstname.lastname@example.org
Västra Hamnen Corporate Finance
Tel. (+46) 40 200 250, email: email@example.com
ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.
The company was founded in 2000 based on the discovery that suPAR was predictive of outcome in HIV-infections and subsequently in many other disease areas. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Spain, and France, while distributors serve other markets.
ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.
About suPAR and suPARnostic®
suPAR is the biomarker detected by ViroGates’ suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 600 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.
The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by 34% and reducing the average hospital length-of-stay by 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics’ cobas, instruments, Siemens ADVIA XPT instruments and the Abbott Labs Architect instruments. ViroGates works with partners to develop solutions for other platforms.
Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.
- Jakob Knudsen, CEO, +45 2226 1355, firstname.lastname@example.org